Tri-VyLibra® Lo

(norgestimate and ethinyl estradiol tablets, USP) 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg

Tri-VyLibra® Lo is an AB-rated generic oral contraceptive.

Compares to

Ortho Tri-Cyclen® Lo, Tri-Lo-Estarylla™, Tri-Lo-Marzia™, and Tri-Lo-Sprintec®

NDC#

50102-231-13

View Full Prescribing Information, Including Boxed Warning

Product Details

  • A progestin/estrogen combination oral contraceptive
  • Triphasic administration regimen
    • 7 white to off white tablets each containing 0.180 mg norgestimate and 0.025 mg ethinyl estradiol
    • 7 pale blue to bluish white tablets each containing 0.215 mg norgestimate and 0.025 mg ethinyl estradiol
    • 7 blue to light blue tablets each containing 0.250 mg norgestimate and 0.025 mg ethinyl estradiol
    • 7 green placebo tablets to help ease administration
    • Combined in a 28-day tablet blister pack

Product Sheet

The Product Information Sheet features a summary of all relevant product information including Tri-VyLibra® Lo (norgestimate and ethinyl estradiol tablets, USP) 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg product details, product description, NDC number, and product features.

Download Now

Product Features:

  • Tri-VyLibra Lo may make periods lighter and shorter than usual

Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on combination oral contraceptives (COCs), especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. Some women may experience amenorrhea or oligomenorrhea after discontinuation of COCs, especially when such a condition was pre-existent.

The most common adverse reactions associated with Tri-VyLibra Lo include headache/migraine, nausea/vomiting, breast issues, abdominal pain, menstrual disorders, mood disorders, acne, vulvovaginal infection, abdominal distension, weight increased, and fatigue.

Use of COCs increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes). This risk increases with age, particularly in women over 35 years of age who smoke.

View Full Prescribing Information, Including Boxed Warning

Distributor & Ordering Info

Tri-VyLibra® Lo

NDC#: 50102-231-13

Package Size: A Carton Containing 3 Packages

Distributor Phone URL Order Number
ANDA 1-800-331-2632 (Ext. 74591) andanet.com 329111
ASD Healthcare 1-800-746-6273 asdhealthcare.com 53776
Cardinal Health 1-800-326-6457 cardinalhealth.com 5507397
McKesson 1-855-625-6285 mckesson.com 3564150
Morris & Dickson 1-888-376-7409 morrisdickson.com 551184
R & S Northeast 1-800-262-7770 rsnortheast.com 0231130

Order Tri-VyLibra® Lo
(norgestimate and ethinyl estradiol tablets, USP)

Order Now

Contact Your
Afaxys Pharma
Account Manager

Contact Now

View All
Afaxys Pharma
Products

View Now